Cure My Disease

Don't miss your cure!

 Log in / Sign up

Team approach aims to boost cancer pill adherence and safety

NCT ID NCT01370980

Disease control Sponsor: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests a support program that brings together oncologists, pharmacists, doctors, and nurses to help cancer patients take their oral medications as prescribed. The goal is to improve treatment effectiveness and patient safety by ensuring better communication and follow-up. Adults 18 and older being treated for cancer with specific oral drugs can take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a support program involving oncologists, pharmacists, physicians, and nurses to improve medication adherence
What this could lead to
If successful, this approach could improve how well cancer patients follow their oral treatment plans and reduce complications.
What could go wrong
This is a small, early-stage study with only 43 participants, so results may not apply broadly. The program's success depends on many factors, including patient motivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

43 people

The number who actually took part.

Start date

Jul 2010

Finished

Sep 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with cancer treated by oral medication in swiss-romande hospitals and private oncologists, and enrolled in the adherence program in one of the thirty studies pharmacies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years and older * Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox) * French speaking Exclusion Criteria: \- None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Medication Adherence neoplasm Patient Acceptance of Health Care Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Policlinique Médicale Universitaire and Centre pluridisciplinaire d'oncologie, CHUV

    Lausanne, Canton of Vaud, 1010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.